Echocardiographic Analysis by Artificial Intelligence in Hypertension
Launched by HOSPICES CIVILS DE LYON · Nov 7, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help us better understand heart changes in people with high blood pressure, also known as arterial hypertension. By analyzing routine heart imaging tests, called echocardiograms, along with patient information, the researchers aim to develop tools that can automatically measure and describe heart function more accurately. This could help doctors better track the progression of heart issues in patients, especially those whose conditions are not easy to categorize.
To participate in this study, individuals must be between the ages of 65 and 74 and have undergone a thorough blood pressure evaluation while hospitalized at specific cardiology clinics in Lyon, France, between 2018 and 2021. Unfortunately, younger individuals or those who are under guardianship cannot take part. If eligible, participants can expect to contribute to important research that may improve how we monitor and treat heart conditions related to high blood pressure. The trial is currently recruiting new participants.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria Patients who underwent a comprehensive blood pressure assessment during hospitalization in the Cardiologic Federation at Croix Rousse Hospital and Lyon Sud Hospital between January 2018 and December 2021.
- • Exclusion Criteria Patients who are minors. Patients under curatorship or guardianship.
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pierre Bénite, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported